【摘要】 目的:评价口服蛋白酶体抑制剂伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性。方法:回顾性分析2019年1月至2020年12月在安徽医科大学第一附属医院血液科接受含伊沙佐米治疗的多发性骨髓瘤患者80例,其中复发/难治(relapsed/refractory multiple myeloma, RRMM)患者38例,硼替佐米初始诱导治疗有效而因不良事件(adverse events, AEs)转换治疗患者42例,治疗方案为含伊沙佐米的两药或三药方案。评价伊沙佐米的临床疗效和安全性。结果:RRMM患者总体反应率(ORR)为50%,≥非常好的部分缓解(VGPR)率为21.05%;转换治疗患者ORR为83.33%,与转换前ORR(78.57%)相比,缓解率进一步提高,其中45.24%(19/42)患者缓解加深;主要的血液学AEs包括粒细胞和血小板计数减少以及贫血,非血液学AEs主要是腹泻和乏力等。结论:伊沙佐米对RRMM、硼替佐米不耐受MM均表现出良好的临床疗效和安全性。更多还原

【Abstract】 AIM: To evaluate the clinical efficacy and safety of oral proteasome inhibitor ixazomib in the treatment of multiple myeloma. METHODS: Eighty patients with multiple myeloma treated with ixazomib-containing therapy in the department of hematology, the First Affiliated Hospital of Anhui Medical University from January 2019 to December 2020 were retrospectively analyzed, including 38 patients with relapsed/refractory multiple myeloma(RRMM)and 42 patients who switched treatment due to adverse events(AEs) after initial induction therapy with bortezomib. Treatment was a two-drug or three-drug regimen containing ixazomib, and the clinical efficacy and safety of ixazomib were evaluated. RESULTS: The overall response rate(ORR) of relapsed/refractory patients was 50%, ≥ VGPR 21.05%; the ORR of patients who switched treatment was 83.33%, compared with the ORR before switching(78.57%), the response rate was further improved, of which 45.24%(19/42) patients had deepened response; the main hematological AEs included granulocyte and platelet count reduction and anemia, non-hematological AEs were mainly diarrhea and fatigue. CONCLUSION: Ixazomib shows good clinical efficacy and safety in patients with RRMM and bortezomib-intolerant MM.更多还原